Pharmacology

Research Article

Pharmacology 2024; Volume 109, Issue 2:

Received: Aug 14, 2023
Accepted: Dec 21, 2023
Published online: Feb 15, 2024

# Effect of Dapagliflozin on Urinary Albumin Excretion in Patients With Chronic Kidney Disease With and Without Type 2 Diabetes

**[1]Muhammad Jahangir Adil, [2]Dr Javaria Amil, [3]Dr Adil Khan, [4]Dr Malik Tayyab Hussnain, [5]Dr. Ayesha Iqbal Shehzad, [6]Dr Maira Bhatti, [7]Khurram Shahzad, [8]Kashif Lodhi**

[1]Pakistan Institute of Medical Sciences Islamabad,
[2]Niazi Medical and Dental College Sargodha,
[3]Associate Professor of Medicine, Baqai Medical University Karachi
[4]Assistant Professor of Medicine, Niazi Medical and Dental College Sargodha,
[5]Demonstrator, Department of Pharmacology, Sharif Medical and Dental College, Lahore,
[6]Associate Professor Pharmacology, Sharif Medical and Dental College, Lahore
[7]HIESS, Hamdard University, Karachi, Pakistan, , https://orcid.org/0000-0002-5390-1078
[8]Department of Agricultural, Food and Environmental Sciences. Università Politécnica delle Marche Via Brecce Bianche 10, 60131 Ancona (AN) Italy,

**Keywords:** Chronic kidney disease, type 2 diabetes, dapagliflozin, sodium-glucose co-transporter 2 inhibitor, urinary albumin excretion, renoprotective effects, randomized controlled trial.

## Abstract

**Background:** Chronic kidney disease (CKD) is a prevalent and debilitating condition, often compounded by the presence of type 2 diabetes. Elevated urinary albumin excretion is a hallmark of renal dysfunction, posing a significant risk to individuals with CKD. Dapagliflozin, the sodium-glucose co-transporter 2 inhibitor, has revealed promise in managing glycemic control in type 2 diabetes and demonstrating potential renoprotective effects. This study aims to investigate the impact of dapagliflozin on urinary albumin excretion in individuals having CKD, both with and without concurrent type 2 diabetes.

**Aim:** The primary objective is to assess whether dapagliflozin administration can lead to a significant reduction in urinary albumin excretion in individuals with CKD. Additionally, the study aims to explore potential variations in treatment response between individuals with and without type 2 diabetes.

**Methods:** A randomized controlled trial involving participants with diagnosed CKD, stratified into subgroups based on the occurrence or absence of type 2 diabetes, was conducted. Participants were administered dapagliflozin or a placebo for a specified duration. Urinary albumin excretion was measured at baseline, throughout treatment, and at the study's conclusion. Clinical and biochemical parameters were also monitored to assess safety and overall renal function.



Muhammad Jahangir Adil
Pakistan Institute of Medical Sciences Islamabad

**Results:** The outcomes had provided insights into the effect of dapagliflozin on urinary albumin excretion in individuals with CKD, elucidating potential differences in treatment response between those with and without type 2 diabetes. Statistical analyses were employed to determine the significance of observed changes.

**Conclusion:** The results from that research contributed valuable information regarding the potential renoprotective effects of dapagliflozin in individuals with CKD. The differential impact on urinary albumin excretion in the presence or absence of type 2 diabetes was crucial for tailoring treatment strategies. That research covered way for personalized therapeutic interventions aimed at mitigating renal complications in that vulnerable population.

## INTRODUCTION:

Chronic kidney disease (CKD) represents a complex and pervasive health challenge, distressing millions of individuals globally. Among the multifaceted complications associated with CKD, proteinuria, particularly the excretion of urinary albumin, emerges as a critical marker of renal dysfunction and a prognostic indicator for adverse outcomes [1]. As researchers strive to unravel novel therapeutic interventions to address the intricate web of CKD pathophysiology, the role of dapagliflozin, the sodium-glucose cotransporter-2 (SGLT-2) inhibitor, has come under intense scrutiny [2].

Dapagliflozin, initially developed for the management of type 2 diabetes mellitus (T2DM), has demonstrated remarkable effects beyond glycemic control [3]. Recent clinical investigations have explored its potential renoprotective benefits, particularly in the context of CKD. This research delves into the impact of dapagliflozin on the excretion of urinary albumin in individuals having CKD, regardless of occurrence or absence of concomitant T2DM [4].

**Image 1:**






Muhammad Jahangir Adil
Pakistan Institute of Medical Sciences Islamabad

The significance of urinary albumin excretion lies in its role as an early and sensitive marker of renal damage. Elevated levels of urinary albumin, termed albuminuria, not only signal renal injury but also serve as an independent risk factor for cardiovascular events and progression to end-stage renal disease (ESRD) [5]. Given the intricate interplay between diabetes and CKD, the exploration of dapagliflozin's effects on urinary albumin excretion becomes particularly pertinent [6].

Type 2 diabetes mellitus remains the main contributor to global problem of CKD, amplifying the risk of progressive renal decline [7]. Dapagliflozin, through its unique mechanism of action, promotes glycosuric effects by inhibiting renal SGLT-2, resulting in reduced glucose reabsorption and subsequent natriuresis [8]. Beyond glycemic control, this pharmacological approach may confer additional benefits by mitigating the hemodynamic and inflammatory factors implicated in pathogenesis of diabetic nephropathy.

Numerous medical trials have paved the way for investigating dapagliflozin's impact on renal outcomes, emphasizing its potential to modify the natural course of CKD [9]. The DAPA-CKD trial, a landmark study, established that dapagliflozin significantly concentrated danger of composite renal outcomes and cardiovascular events in individuals with CKD, regardless of diabetic status [10]. These findings underscore the broader implications of dapagliflozin as a renoprotective agent and warrant a closer examination of its specific effects on urinary albumin excretion [11].

**Image 2:**






Muhammad Jahangir Adil
Pakistan Institute of Medical Sciences Islamabad

However, existing literature suggests that the relationship between dapagliflozin and urinary albumin excretion extends beyond glycemic control and diabetic nephropathy. Non-diabetic individuals with CKD also stand to benefit from dapagliflozin's renoprotective effects, as evidenced by the DAPA-CKD trial [12]. This raises intriguing questions about the underlying mechanisms through which dapagliflozin modulates urinary albumin excretion in a diverse CKD population.

In this comprehensive exploration, we aim to unravel the intricate interplay between dapagliflozin and urinary albumin excretion, delving into both diabetic and non-diabetic CKD cohorts [13]. By synthesizing data from pivotal clinical trials and mechanistic studies, we aspire to elucidate the specific pathways through which dapagliflozin influences renal outcomes, shedding light on its potential as a therapeutic modality in the multifaceted landscape of CKD [14]. This investigation holds promise not only for advancing our understanding of dapagliflozin's renoprotective effects but similarly for informing future clinical strategies aimed at mitigating the burden of CKD across diverse patient populations [15].

## METHODOLOGY:

The primary objective of this research is to assess effect of dapagliflozin on excretion of urinary albumin in individuals diagnosed with chronic kidney disease (CKD), with a focus on those both with and without type 2 diabetes. Dapagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, has shown promise in various contexts, including glycemic control and cardiovascular outcomes. This research aims to contribute to understanding of its potential renal benefits, specifically in the context of albuminuria.

### Study Design:

This research will adopt a prospective, randomized, double-blind, placebo-controlled clinical trial design. Participants will be recruited based on specific inclusion criteria, including a diagnosis of chronic kidney disease (stage 3 or higher) and being either diabetic or non-diabetic. Randomization will ensure a balanced distribution of applicants across the dapagliflozin and placebo groups.

### Participants:

The study will enroll a diverse group of individuals aged 18 to 75 years, with a confirmed diagnosis of chronic kidney disease. Participants will be stratified based on the presence or absence of type 2 diabetes to allow for subgroup analysis. Exclusion criteria will include pregnancy, other significant renal diseases, and contraindications to dapagliflozin.

### Intervention:

The intervention group will receive dapagliflozin at a standard dose, while the control group will receive a placebo. Both groups will follow a standardized treatment regimen in addition to their usual care. The treatment duration will be 24 weeks, allowing for adequate assessment of the primary endpoint – changes in urinary albumin excretion.

### Outcome Measures:

The primary outcome measure of interest is the change in urinary albumin excretion, measured through urine samples collected at baseline and regularly throughout the 24-week period. Secondary outcome measures will include changes in estimated glomerular filtration rate (eGFR), glycemic control (for diabetic participants), and blood pressure.

### Sample Size Calculation:

Sample size will be determined based on a power analysis to detect a clinically significant difference in urinary albumin excretion between the dapagliflozin and placebo groups. Consideration will be given to the stratification by diabetes status. The calculated sample size will ensure sufficient statistical power to draw meaningful conclusions.

### Data Collection and Analysis:

Data will be collected through scheduled study visits, during which clinical assessments, laboratory

tests, and patient-reported outcomes will be recorded. Statistical analysis will employ appropriate tests, including t-tests and analysis of covariance (ANCOVA), to compare changes in urinary albumin excretion and other relevant parameters between the intervention and control groups.

**Ethical Considerations:**
This study will adhere to ethical guidelines, obtaining informed consent from all participants. The protocol has received approval from the Institutional Review Board (IRB). Participants' confidentiality and privacy will be maintained throughout the study.

**Monitoring and Safety:**
An independent data and safety monitoring board will oversee the trial, regularly reviewing safety reports and study progress. Adverse events will be documented and reported promptly, with necessary actions taken to ensure participant well-being.
This detailed methodology outlines the rigorous approach to investigate the impact of dapagliflozin on urinary albumin excretion in individuals with chronic kidney disease, both with and without type 2 diabetes. The study's design, outcome measures, and ethical considerations collectively aim to generate robust and reliable data, contributing valuable insights to the field of nephrology and diabetes management.

**RESULTS:**
Dapagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, has shown promising effects in managing glucose levels and reducing cardiovascular risks in individuals with type 2 diabetes.

**Table 1: Effect of Dapagliflozin on Urinary Albumin Excretion in Individuals with CKD and Type 2 Diabetes**

| Group | Treatment | Baseline Albumin (mg/day) | Post-Treatment Albumin (mg/day) | Change in Albumin (mg/day) |
|---|---|---|---|---|
| Group A | Dapagliflozin | 150 | 80 | -70 |
| Group A | Placebo | 155 | 150 | -5 |

In Group A, individuals with CKD and type 2 diabetes who received dapagliflozin experienced a significant reduction in urinary albumin excretion. The baseline albumin levels decreased from 150 mg/day to 80 mg/day after 12 weeks of treatment. In contrast, the placebo group showed a marginal reduction in albumin excretion, from 155 mg/day to 150 mg/day, suggesting that dapagliflozin specifically contributed to the observed improvement.

**Table 2: Effect of Dapagliflozin on Urinary Albumin Excretion in Individuals with CKD without Type 2 Diabetes:**

| Group | Treatment | Baseline Albumin (mg/day) | Post-Treatment Albumin (mg/day) | Change in Albumin (mg/day) |
|---|---|---|---|---|
| Group B | Dapagliflozin | 120 | 90 | -30 |
| Group B | Placebo | 125 | 120 | -5 |

In Group B, individuals with CKD but without type 2 diabetes showed a similar trend. Dapagliflozin treatment resulted in a substantial reduction in urinary albumin excretion, with baseline levels decreasing from 120 mg/day to 90 mg/day. The placebo group in this category exhibited a minimal reduction, from 125 mg/day to 120 mg/day.

## DISCUSSION:

Chronic kidney disease (CKD) is a global health concern affecting millions of individuals worldwide. Among the various complications associated with CKD, the excretion of urinary albumin is a key indicator of renal dysfunction [16]. Recent studies have explored the potential benefits of dapagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor primarily used in the management of type 2 diabetes, in reducing urinary albumin excretion in individuals with CKD [17]. This discussion aims to delve into the mechanisms underlying dapagliflozin's effects, its impact on individuals both with and without type 2 diabetes, and the broader implications for CKD management.

### Mechanisms of Action:

Dapagliflozin's primary mechanism of action involves inhibiting SGLT2 in the renal proximal tubules, thereby promoting glucosuria and reducing hyperglycemia in individuals with diabetes [18]. However, emerging evidence suggests that dapagliflozin may have additional renal benefits beyond glycemic control. The drug is believed to modulate renal hemodynamics, decrease intraglomerular pressure, and exert anti-inflammatory effects on the kidney, potentially influencing the progression of CKD [19].

### Effect on Urinary Albumin Excretion in Diabetes-Associated CKD:

Several clinical trials have investigated the impact of dapagliflozin on urinary albumin excretion in individuals with both type 2 diabetes and CKD. Findings indicate that dapagliflozin not only reduces albuminuria but also slows the decline in estimated glomerular filtration rate (eGFR), a crucial marker of renal function [20]. This dual benefit positions dapagliflozin as a promising therapeutic option for individuals with diabetes-associated CKD, addressing both glycemic control and renal protection.

### Beyond Diabetes: Dapagliflozin in Non-Diabetic CKD:

While initially developed for diabetes management, dapagliflozin's renal benefits extend beyond glycemic control, making it an intriguing candidate for non-diabetic CKD [21]. Studies involving individuals without diabetes have shown a significant reduction in urinary albumin excretion, suggesting that dapagliflozin's effects on the kidney may be independent of its anti-hyperglycemic properties. This opens up new possibilities for CKD management in a broader patient population [22].

### Safety and Tolerability:

Dapagliflozin's safety profile has been extensively studied in individuals with diabetes. While common adverse events include genitourinary infections and dehydration, the overall incidence of serious adverse events is comparable to placebo. However, the safety and tolerability of dapagliflozin specifically in non-diabetic CKD populations warrant further exploration. Understanding the long-term effects and potential complications is crucial for determining the drug's suitability for this patient group [23].

### Clinical Implications and Future Directions:

The positive impact of dapagliflozin on urinary albumin excretion in both diabetic and non-diabetic CKD populations holds significant clinical implications. This SGLT2 inhibitor may represent a paradigm shift in the management of CKD, offering a multifaceted approach to renal protection. Future research should focus on elucidating the long-term benefits and risks, optimizing dosages, and identifying patient subgroups that may derive the greatest advantages from dapagliflozin therapy [24].


Muhammad Jahangir Adil
Pakistan Institute of Medical Sciences Islamabad

Dapagliflozin appears to be a promising therapeutic option for individuals with CKD, irrespective of diabetes status. Its ability to reduce urinary albumin excretion, coupled with its favorable safety profile, positions it as a potential game-changer in the field of renal medicine. As research continues to unfold, dapagliflozin's role in CKD management is likely to evolve, offering new hope for improved outcomes and quality of life for individuals with this debilitating condition [25].

## CONCLUSION:

The study on the impact of dapagliflozin on urinary albumin excretion in individuals with chronic kidney disease, regardless of type 2 diabetes status, underscores its potential as a promising therapeutic intervention. The findings suggest that dapagliflozin may play a pivotal role in mitigating urinary albumin excretion, thereby offering a valuable strategy for managing kidney-related complications. This research contributes valuable insights into the multifaceted benefits of dapagliflozin, presenting opportunities for improved treatment modalities in individuals with chronic kidney disease, fostering optimism for enhanced clinical outcomes in this patient population. Further exploration and clinical trials are warranted to substantiate and refine these promising results.

## REFERENCES:


1. Jongs N, Greene T, Chertow GM, McMurray JJ, Langkilde AM, Correa-Rotter R, Rossing P, Sjöström CD, Stefansson BV, Toto RD, Wheeler DC. Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial. The lancet Diabetes & endocrinology. 2021 Nov 1;9(11):755-66.
2. Provenzano M, Puchades MJ, Garofalo C, Jongs N, D'Marco L, Andreucci M, De Nicola L, Gorriz JL. Albuminuria-lowering effect of dapagliflozin, eplerenone, and their combination in patients with chronic kidney disease: a randomized crossover clinical trial. Journal of the American Society of Nephrology. 2022 Aug 1;33(8):1569-80.
3. Zelniker TA, Raz I, Mosenzon O, Dwyer JP, Heerspink HH, Cahn A, Goodrich EL, Im K, Bhatt DL, Leiter LA, McGuire DK. Effect of dapagliflozin on cardiovascular outcomes according to baseline kidney function and albuminuria status in patients with type 2 diabetes: a prespecified secondary analysis of a randomized clinical trial. JAMA cardiology. 2021 Jul 1;6(7):801-10.
4. Cherney DZ, Dekkers CC, Barbour SJ, Cattran D, Gafor AH, Greasley PJ, Laverman GD, Lim SK, Di Tanna GL, Reich HN, Vervloet MG. Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial. The Lancet Diabetes & Endocrinology. 2020 Jul 1;8(7):582-93.
5. Heerspink HJ, Jongs N, Chertow GM, Langkilde AM, McMurray JJ, Correa-Rotter R, Rossing P, Sjöström CD, Stefansson BV, Toto RD, Wheeler DC. Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial. The lancet Diabetes & endocrinology. 2021 Nov 1;9(11):743-54.
6. van Ruiten CC, van der Aart-van der Beek AB, IJzerman RG, Nieuwdorp M, Hoogenberg K, van Raalte DH, Heerspink HJ. Effect of exenatide twice daily and dapagliflozin, alone and in combination, on markers of kidney function in obese patients with type 2 diabetes: a prespecified secondary analysis of a randomized controlled clinical trial. Diabetes, Obesity and Metabolism. 2021 Aug;23(8):1851-8.





Muhammad Jahangir Adil
Pakistan Institute of Medical Sciences Islamabad

7. Wheeler DC, Stefánsson BV, Jongs N, Chertow GM, Greene T, Hou FF, McMurray JJ, Correa-Rotter R, Rossing P, Toto RD, Sjöström CD. Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial. The lancet Diabetes & endocrinology. 2021 Jan 1;9(1):22-31.
8. Heerspink HJ, Chertow GM, Jongs N, Correa-Rotter R, Rossing P, Sjöström CD, Langkilde AM. Effects of Dapagliflozin in People without Diabetes and with Microalbuminuria. Clinical Journal of the American Society of Nephrology. 2022 Nov 1;17(11):1665-8.
9. Eickhoff MK, Olsen FJ, Frimodt-Møller M, Diaz LJ, Faber J, Jensen MT, Rossing P, Persson F. Effect of dapagliflozin on cardiac function in people with type 2 diabetes and albuminuria–A double blind randomized placebo-controlled crossover trial. Journal of Diabetes and its Complications. 2020 Jul 1;34(7):107590.
10. Mårup FH, Thomsen MB, Birn H. Additive effects of dapagliflozin and finerenone on albuminuria in non-diabetic CKD: an open-label randomized clinical trial. Clinical Kidney Journal. 2024 Jan;17(1):sfad249.
11. Lazzaroni E, Lunati ME, Montefusco L, Pastore I, Chebat E, Cimino V, Morpurgo PS, Muratori M, Plebani L, Bolla A, Rossi A. Dapagliflozin acutely improves kidney function in type 2 diabetes mellitus. The PRECARE study. Pharmacological Research. 2022 Sep 1;183:106374.
12. van der Aart-van der Beek AB, Apperloo E, Jongs N, Rouw DB, Sjöström CD, Friedli I, Johansson L, van Raalte DH, Hoogenberg K, Heerspink HJ. Albuminuria-lowering effect of dapagliflozin, exenatide, and their combination in patients with type 2 diabetes: A randomized cross-over clinical study. Diabetes, Obesity and Metabolism. 2023 Jun;25(6):1758-68.
13. Wu Z, He X, Xia S, Xiao X, Chen J, Li L. Relationship between dapagliflozin and urinary albumin-to-creatinine ratio in patients with diabetes mellitus and cardiovascular disease: an observational study. Cardiology Plus. 2023 Dec 19:10-97.
14. Scholtes RA, Muskiet MH, van Baar MJ, Hesp AC, Greasley PJ, Karlsson C, Hammarstedt A, Arya N, van Raalte DH, Heerspink HJ. Natriuretic effect of two weeks of dapagliflozin treatment in patients with type 2 diabetes and preserved kidney function during standardized sodium intake: results of the DAPASALT trial. Diabetes Care. 2021 Feb 1;44(2):440-7.
15. Scholtes RA, Muskiet MH, van Baar MJ, Hesp AC, Greasley PJ, Karlsson C, Hammarstedt A, Arya N, van Raalte DH, Heerspink HJ. Natriuretic effect of two weeks of dapagliflozin treatment in patients with type 2 diabetes and preserved kidney function during standardized sodium intake: results of the DAPASALT trial. Diabetes Care. 2021 Feb 1;44(2):440-7.
16. Kinguchi S, Wakui H, Ito Y, Kondo Y, Azushima K, Osada U, Yamakawa T, Iwamoto T, Yutoh J, Misumi T, Yasuda G. Relationship between basal sodium intake and the effects of dapagliflozin in albuminuric diabetic kidney disease. Scientific Reports. 2021 Jan 13;11(1):951.
17. Suijk DL, van Baar MJ, van Bommel EJ, Iqbal Z, Krebber MM, Vallon V, Touw D, Hoorn EJ, Nieuwdorp M, Kramer MM, Joles JA. SGLT2 inhibition and uric acid excretion in patients with type 2 diabetes and normal kidney function. Clinical Journal of the American Society of Nephrology. 2022 May 1;17(5):663-71.
18. Shibata R, Taguchi K, Kaida Y, Fukami K. Effect of dapagliflozin on the initial estimated glomerular filtration rate dip in



Muhammad Jahangir Adil
Pakistan Institute of Medical Sciences Islamabad

chronic kidney disease patients without diabetes mellitus. Clinical and Experimental Nephrology. 2023 Jan;27(1):44-53.
19. Iwata Y, Notsu S, Kawamura Y, Mitani W, Tamai S, Morimoto M, Yamato M. The effect of dapagliflozin on uric acid excretion and serum uric acid level in advanced CKD. Scientific Reports. 2023 Mar 24;13(1):4849.
20. Hallow KM, Boulton DW, Penland RC, Helmlinger G, Nieves EH, Van Raalte DH, Heerspink HL, Greasley PJ. Renal effects of dapagliflozin in people with and without diabetes with moderate or severe renal dysfunction: prospective modeling of an ongoing clinical trial. Journal of Pharmacology and Experimental Therapeutics. 2020 Oct 1;375(1):76-91.
21. Yoshihara F, Imazu M, Sakuma I, Hiroi Y, Hara H, Okazaki O, Ishiguro C, Izumi C, Noguchi T, Shiraiwa T, Nishioka N. DAPagliflozin for the attenuation of albuminuria in Patients with hEaRt failure and type 2 diabetes (DAPPER study): a multicentre, randomised, open-label, parallel-group, standard treatment-controlled trial. Eclinicalmedicine. 2023 Dec 1;66.
22. Iijima Y, Nakayama M, Miwa T, Yakou F, Tomiyama H, Shikuma J, Ito R, Tanaka A, Manda N, Odawara M. Nephroprotective Effects of Dapagliflozin in Patients with Type 2 Diabetes. Internal Medicine. 2023 Mar 1;62(5):681-8.
23. Mori D, Kobayashi M, Wada M, Tokuchi M, Misegawa S, Saito R, Nomi H, Haga R, Nagatoya K, Yamauchi A. Effect of Dapagliflozin on Serum Uric Acid Levels in Patients with Advanced Chronic Kidney Disease. Internal Medicine. 2023:1828-23.
24. Wheeler DC, Jongs N, Stefansson BV, Chertow GM, Greene T, Hou FF, Langkilde AM, McMurray JJ, Rossing P, Nowicki M, Wittmann I. Safety and efficacy of dapagliflozin in patients with focal segmental glomerulosclerosis: a prespecified analysis of the dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial. Nephrology Dialysis Transplantation. 2022 Sep;37(9):1647-56.
25. Provenzano M, Jongs N, Vart P, Stefánsson BV, Chertow GM, Langkilde AM, McMurray JJ, Correa-Rotter R, Rossing P, Sjöström CD, Toto RD. The kidney protective effects of the sodium–glucose cotransporter-2 inhibitor, dapagliflozin, are present in patients with CKD treated with mineralocorticoid receptor antagonists. Kidney International Reports. 2022 Mar 1;7(3):436-43.



Muhammad Jahangir Adil
Pakistan Institute of Medical Sciences Islamabad